Improvement of glycemic control after a 3-5 day insulin infusion in type 2-diabetic patients with insulin resistance can be maintained with glitazone therapy

Wiener Klinische Wochenschrift

Volumn 118, Issue 17-18, 2006, Pages 543-548

  Biesenbach, Georg ^a   Grafinger, Peter ^a   Raml, Andreas ^a  

^a KEPLER UNIVERSITY HOSPITAL   (Austria)

Author keywords

Glitazone; Insulin infusion; Insulin resistance; Type 2 diabetes

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIURETIC AGENT; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PIOGLITAZONE; SEX HORMONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIURETIC THERAPY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HORMONAL THERAPY; HUMAN; INSULIN INFUSION; INSULIN RESISTANCE; KIDNEY FAILURE; LIVER DISEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CHI-SQUARE DISTRIBUTION; DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; OVERWEIGHT; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 33750035469     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-006-0656-4     Document Type: Article

References (22)

1. Del Prato S (1999) Measurement of insulin resistance in vivo. Drugs 58 [Suppl 1]: 75-82
2. Pliats (1978) Treatment of insulin-resistant form of diabetes mellitus by intravenous droplet infusion of insulin. Probl Endokrinol 24: 14-17
3. Gelding SV, Coldham N, Niththyananthan R, Anayaoku V, Johnston DG (1995) Insulin resistance with respect to lipolysis in non-diabetic relatives of European patients with type 2 diabetes. Diabet Med 12: 66-73
4. Kruszynska YT, Harry DS, Bergmann RN, McIntyre N (1993) Insulin sensitivity, insulin secretion and glucose effectiveness in diabetic and non-diabetic cirrhotic patients. Diabetologia 36: 121-128
5. Reneland R, Alvarez E, Andersson PE, Haenni A, Byberg L, Lithell H (2000) Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril. J Hum Hypertens 14: 175-180
6. Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D (2003) Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomised controlled trial. Diabetes Care 26: 138-143
7. Morita H, Oki Y, Ito T, Ohichi H, Suzuki S, Nakamura H (2003) Administration of troglitazone, but not pioglitazone, reduces insulin resistance caused by short-term dexamethasone (DXM) treatment by accelerating the metabolism of DXM. Diabetes Care 24: 788-789
8. Schade DS, Druckworth WC (1986) In search of the subcutaneous-insulin- resistance syndrome. N Engl J Med 315: 147-153
9. Samanta A, Burden AC, Jones GR, Clarkson L (1986) The effect of short-term intensive insulin therapy in non-insulin-dependent diabetics who had failed on sulphonylurea therapy. Diabetes Res 3: 269-271
10. Gill GV, Husband DJ, Wright PD, Sharpe G, Taylor R, Walford S, Marshall SM, Alberti KG (1986) The management of severe brittle diabetes with "Infusaid" implantable pumps. Diabetes Res 3: 135-137
11. Buchwald H, Chute EP, Goldenberg FJ, Hitchcock CR, Hoogwerf BJ, Barbosa JJ, Rupp WM, Rohde TD (1985) Implantable infusion pump management of insulin resistant diabetes mellitus. Ann Surg 202: 278-282
12. Lohmann D, Janusch H, Bemm H, Rotzsch W, Kluge HO (1986) Intravenous insulin treatment of chronic insulin resistance. Dtsch Z Verdau Stoffwechselkr 28: 337-344
13. Pouwels MJ, Tack CJ, Hermus AR, Lutterman JA (2003). Treatment with intravenous insulin followed by continuous subcutaneous insulin infusion improves glycaemic control in severely resistant type 2 diabetic patients. Diabet Med 20: 76-79
14. Lechleitner M, Roden M, Haehling E, Muellner M (2005) Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus. Wien Klin Wochenschr 117: 593-598
15. Sekino N, Kashiwabara A, Inoue T, Kawasaki T, Ogata N, Sawashige K, Yamanouchi T (2004) Usefulness of troglitazone administration to obese hyperglycaemic patients with near-normoglycaemia. Diabetes, Obesity and Metabolism 3: 145-149
16. Engl J, Hanusch-Enserer U, Prager R, Patsch JR, Ebenbichler C (2005) The metabolic syndrome: effects of a pronounced weight loss induced by bariatric surgery. Wien Klin Wochenschr 117: 243-54
17. Poulsen MK, Henriksen JF, Hother-Nielsen O, Beck Nielsen H (2003) The combined effect of triple therapy with rosiglitazone and insulin aspart in type 2 diabetic patients. Diabetes Care 26: 3273-3279
18. Schernthaner G (1994) The value of metformin in therapy of type 2 diabetes: effect on insulin resistance, diabetic control and cardiovascular risk factor. Wien Klin Wochenschr 102: 793-802
19. Stingl H, Roden M (2004). Future targets in the treatment of type 2 diabetes. Wien Klin Wochenschr 116: 217-29
20. Gillies PS, Dunn CJ (2000) Pioglitazone. Drug 60: 333-343
21. Mingrone G, DeGaetano A, Greco AV, Capristo E, Benedetti G, Castagneto M, Gasbarrini G (1997) Reversibility of insulin resistance in obese diabetic patients: role of plasma lipids. Diabetologia 40: 599-605
22. Shulman GI (2000) Cellular mechanisms of insulin resistance. J Clin Invest 106: 171-176